Marina Pierdominici

List of Publications by Year
in descending order

56	7,073	201575	149623
papers	citations	27 h-index	56 g-index

56	56	56	16885
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma. Anticancer Research, 2022, 42, 767-779.	0.5	4
2	Prevalence and Correlates of Sexually Transmitted Infections in Transgender People: An Italian Multicentric Cross-Sectional Study. Journal of Clinical Medicine, 2022, 11, 2774.	1.0	4
3	The role of vitamin D in autoimmune diseases: could sex make the difference?. Biology of Sex Differences, 2021, 12, 12.	1.8	53
4	Synergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19. Frontiers in Pharmacology, 2021, 12, 683529.	1.6	4
5	Hormonal Treatment Effect on Sexual Distress in Transgender Persons: 2-Year Follow-Up Data. Journal of Sexual Medicine, 2020, 17, 142-151.	0.3	24
6	Autoantibodies Specific to ERÎ± are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. Cells, 2019, 8, 750.	1.8	8
7	Editorial: Sex Hormones and Gender Differences in Immune Responses. Frontiers in Immunology, 2019, 10, 1076.	2.2	80
8	Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2019, 10, 47.	1.6	14
9	The Natural Agonist of Estrogen Receptor Î² Silibinin Plays an Immunosuppressive Role Representing a Potential Therapeutic Tool in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 1903.	2.2	39
10	Distinct Blood and Visceral Adipose Tissue Regulatory T Cell and Innate Lymphocyte Profiles Characterize Obesity and Colorectal Cancer. Frontiers in Immunology, 2017, 8, 643.	2.2	60
11	CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary SjÃ¶grenâ€™s syndrome patients and correlates with focus score and disease activity. Arthritis Research and Therapy, 2017, 19, 178.	1.6	41
12	Estrogen receptor Î² ligation inhibits Hodgkin lymphoma growth by inducing autophagy. Oncotarget, 2017, 8, 8522-8535.	0.8	47
13	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
14	Low expression of estrogen receptor Î² in T lymphocytes and high serum levels of anti-estrogen receptor Î± antibodies impact disease activity in female patients with systemic lupus erythematosus. Biology of Sex Differences, 2016, 7, 3.	1.8	51
15	Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation. OncoImmunology, 2016, 5, e1074375.	2.1	16
16	Sex-based differences in autoimmune diseases. Annali Dell'Istituto Superiore Di Sanita, 2016, 52, 205-12.	0.2	196
17	Autoantibodies specific to D4GDI modulate Rho GTPase mediated cytoskeleton remodeling and induce autophagy in T lymphocytes. Journal of Autoimmunity, 2015, 58, 78-89.	3.0	21
18	Membrane lipid rafts and estrogenic signalling: a functional role in the modulation of cell homeostasis. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 671-678.	2.2	21

#	Article	IF	Citations
19	Linking estrogen receptor Î² expression with inflammatory bowel disease activity. Oncotarget, 2015, 6, 40443-40451.	0.8	58
20	Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders. FASEB Journal, 2014, 28, 524-535.	0.2	22
21	Diesel exhaust particle exposure in vitro impacts T lymphocyte phenotype and function. Particle and Fibre Toxicology, 2014, 11, 74.	2.8	37
22	Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 260-267.	1.2	17
23	Relationship Between Redox Status and Cell Fate in Immunity and Autoimmunity. Antioxidants and Redox Signaling, 2014, 21, 103-122.	2.5	26
24	Autoantibodies to Estrogen Receptor Î± in Systemic Sclerosis (SSc) as Pathogenetic Determinants and Markers of Progression. PLoS ONE, 2013, 8, e74332.	1.1	19
25	T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB Journal, 2012, 26, 4722-4732.	0.2	138
26	Autoantibodies specific to a peptide of Î²2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood, 2012, 120, 3360-3370.	0.6	50
27	Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB Journal, 2012, 26, 1400-1412.	0.2	137
28	Phase <scp>II</scp> study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2012, 158, 108-119.	1.2	36
29	Autoantibodies to estrogen receptor Î± interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 778-787.	6.7	68
30	Cell Surface Estrogen Receptor Alpha Is Upregulated during Subchronic Metabolic Stress and Inhibits Neuronal Cell Degeneration. PLoS ONE, 2012, 7, e42339.	1.1	26
31	Gender Specific Aspects of Cell Death in the Cardiovascular System. Current Pharmaceutical Design, 2011, 17, 1046-1055.	0.9	18
32	mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases. Current Pharmaceutical Design, 2011, 17, 3888-3897.	0.9	29
33	Estrogen receptor profiles in human peripheral blood lymphocytes. Immunology Letters, 2010, 132, 79-85.	1.1	157
34	Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Clinical Immunology, 2010, 137, 122-133.	1.4	52
35	Pyrimethamine Induces Apoptosis of Melanoma Cells via a Caspase and Cathepsin Double-Edged Mechanism. Cancer Research, 2008, 68, 5291-5300.	0.4	37
36	Progressive Derangement of the T Cell Compartment in a Case of Evans Syndrome. International Archives of Allergy and Immunology, 2008, 145, 258-267.	0.9	3

#	Article	IF	Citations
37	Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases. Current Pharmaceutical Design, 2008, 14, 253-268.	0.9	69
38	T-cell homeostasis: the dark(ened) side of common variable immunodeficiency. Blood, 2008, 112, 446-446.	0.6	12
39	Unravelling the Complexity of T Cell Abnormalities in Common Variable Immunodeficiency. Journal of Immunology, 2007, 178, 3932-3943.	0.4	249
40	Pyrimethamine (2,4-Diamino-5-p-chlorophenyl-6-ethylpyrimidine) Induces Apoptosis of Freshly Isolated Human T Lymphocytes, Bypassing CD95/Fas Molecule but Involving Its Intrinsic Pathway. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1046-1057.	1.3	18
41	Biased T-cell receptor repertoires in patients with chromosome 22q11.2 deletion syndrome (DiGeorge) Tj ETQq1 1 0.784314 rgBT /Ov	1.1	56
42	Persistently Biased T-Cell Receptor Repertoires in HIV-1-Infected Combination Antiretroviral Therapy???Treated Patients Despite Sustained Suppression of Viral Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 140-154.	0.9	21
43	Changes in CCR5 and CXCR4 Expression and Î²-Chemokine Production in HIV-1â€“Infected Patients Treated With Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 122-131.	0.9	23
44	Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood, 2002, 100, 4082-4089.	0.6	82
45	European Surveillance of Immunoglobulin Safetyâ€”Results of Initial Survey of 1243 Patients with Primary Immunodeficiencies in 16 Countries. Clinical Immunology, 2002, 104, 231-236.	1.4	49
46	Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2. Aids, 2001, 15, 11-16.	1.0	21
47	T-Cell Immune Activation in Children with Vertically Transmitted Hepatitis C Virus Infection. Viral Immunology, 2001, 14, 169-179.	0.6	6
48	Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Clinical and Experimental Immunology, 2000, 120, 324-332.	1.1	16
49	T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome. Clinical and Experimental Immunology, 2000, 121, 127-132.	1.1	29
50	Low-Dose IL-2 Reduces Lymphocyte Apoptosis and Increases Naive CD4 Cells in HIV-1 Patients Treated with HAART. Clinical Immunology, 2000, 94, 153-159.	1.4	47
51	HIV Type 1-Induced Inhibition of CD45 Tyrosine Phosphatase Activity Correlates with Disease Progression and Apoptosis, but Not with Anti-CD3-Induced T Cell Proliferation. AIDS Research and Human Retroviruses, 2000, 16, 211-219.	0.5	11
52	Apoptosis in asymptomatic HIV-1 seropositives immunized with HIV-1 env glycoprotein (gp160): Effects of administration of Zidovudine in vivo and interleukin-2 in vitro. Vaccine, 1998, 16, 715-721.	1.7	3
53	Prolif erative Responses to PHA, Anti-CD3 and Antigens in Patients with Lymphoproliferative Disease of Granular Lymphocytes. Acta Haematologica, 1997, 98, 65-71.	0.7	2
54	ILâ€10 Production and CD40L Expression in Patients with Common Variable Immunodeficiency. Scandinavian Journal of Immunology, 1997, 46, 86-90.	1.3	22

#	Article	IF	Citations
55	Immunological Aspects of Patients with HIV-1 Disease following Immunization with Recombinant gp160 (VaxSyn). Antibiotics and Chemotherapy, 1996, 48, 147-154.	0.5	4
56	Immunodeficiency with hyperimmunoglobulinemia M in two female patients is not associated with abnormalities of CD40 or CD40 ligand expression. Journal of Allergy and Clinical Immunology, 1995, 96, 403-410.	1.5	19